Shingrix (Zoster Vaccine) Allergy: Recombinant, Not Live-Attenuated

No. Shingrix contains no hydrolyzed gelatin, no gelatin stabilizer, and no mammalian collagen peptides of any kind. This is a major distinction from the older discontinued Zostavax vaccine, which contained 15.58 mg of hydrolyzed gelatin per dose and was contraindicated in patients with gelatin allergy. Shingrix uses recombinant glycoprotein E produced in Chinese hamster ovary (CHO) cells, combined with the AS01B adjuvant system (MPL plus QS-21 saponin). Patients with confirmed gelatin anaphylaxis who could not receive Zostavax, MMR, Varivax, or other gelatin-containing live vaccines can usually safely receive Shingrix under routine observation. Gelatin allergy is NOT a contraindication or precaution for Shingrix, and no special pre-vaccination testing or desensitization is needed on the basis of gelatin history alone.

Shingrix (GSK) is a recombinant subunit vaccine containing purified varicella-zoster virus glycoprotein E produced in Chinese hamster ovary cells, combined with the AS01B adjuvant system. It contains no live virus, no gelatin, and no egg protein, and is administered as a 2-dose series at 0 and 2 to 6 months to adults ≥50 and immunocompromised adults ≥19. Zostavax (Merck) was a live-attenuated Oka-strain vaccine containing 15.58 mg of hydrolyzed gelatin, administered as a single dose to adults ≥60. Zostavax was discontinued in the US market in November 2020 after Shingrix demonstrated superior efficacy — more than 97% in adults 50 to 69 based on the ZOE-50 trial, compared with approximately 50% for Zostavax. Shingrix also works in immunocompromised patients where Zostavax was contraindicated because of the live virus.

Shingrix achieves exceptional efficacy through the combination of a recombinant antigen (glycoprotein E, the major VZV surface protein involved in cell-to-cell spread) and the AS01B adjuvant system. AS01B contains monophosphoryl lipid A (MPL), a detoxified derivative of bacterial lipopolysaccharide, and QS-21, a purified saponin from the Chilean soapbark tree (Quillaja saponaria). These adjuvants activate the innate immune system more strongly than aluminum-based adjuvants, producing a robust and sustained cell-mediated response against VZV. The ZOE-50 and ZOE-70 randomized trials demonstrated efficacy of more than 97% in adults aged 50 to 69 and more than 91% in adults ≥70, with protection maintained for at least 7 years post-vaccination based on follow-up data published in The New England Journal of Medicine.

The GBS warning is based on post-marketing surveillance data showing approximately 3 additional cases of Guillain-Barré syndrome per million Shingrix doses within 42 days of vaccination, identified in Medicare beneficiary claims data. This is a real but very small absolute increase. The FDA updated the Shingrix safety label to reflect the finding, but ACIP continues to recommend routine use because the benefit of shingles prevention — particularly prevention of postherpetic neuralgia, which can cause years of debilitating pain — substantially outweighs the small GBS risk for most adults ≥50. Patients with a personal history of GBS should discuss individualized risk-benefit with their clinician before receiving Shingrix. Any ascending weakness within 6 weeks of a dose warrants urgent neurological evaluation.

Yes. Shingrix is specifically recommended for immunocompromised adults ≥19 by the Advisory Committee on Immunization Practices (ACIP) because it contains no live virus and poses no risk of disseminated vaccine infection. This is a major advantage over the older live-attenuated Zostavax, which was contraindicated in severe immunocompromise. Immunocompromised populations — patients on chemotherapy, post-transplant immunosuppression, high-dose corticosteroids, or biologic therapies — are at substantially higher background risk of shingles and postherpetic neuralgia, making vaccination particularly valuable. The 2-dose Shingrix series may need timing adjustment relative to chemotherapy cycles or transplant timing, and the specific schedule should be coordinated with the treating specialist.

First, distinguish between reactogenicity and a true allergic reaction. Significant sore arm, fatigue, muscle aches, and low-grade fever lasting 1 to 3 days are expected reactogenicity — signs of a vigorous immune response to the AS01B adjuvant, NOT allergy, and not a contraindication to the second dose. True immediate hypersensitivity signs — hives, angioedema, wheezing, anaphylaxis — appearing within minutes of the injection are different and warrant allergist referral before a second dose. Most suspected reactions turn out on formal allergy workup to be reactogenicity that does not preclude completion, and specialist evaluation often allows safe second-dose administration with or without graded testing. Skipping the second dose should not be the default response to a miserable first-dose experience.

It depends on the specific reaction and suspected allergen. Both Shingrix and the mRNA COVID-19 vaccines contain polysorbate 80 or polyethylene glycol (PEG) derivatives, and there is known cross-reactivity between these excipients in roughly 21 to 30% of confirmed PEG-allergic patients. Patients with a history of anaphylaxis to an mRNA COVID-19 vaccine should undergo allergist evaluation — typically skin testing with PEG and polysorbate preparations — before receiving Shingrix. Patients who had only mild local reactions or expected reactogenicity to the COVID-19 vaccines are generally safe to receive Shingrix with routine observation. The Stone et al. 2019 paper in JACI Practice established polysorbate and PEG hypersensitivity as more common than previously recognized and is the current reference for this cross-reactivity discussion.

Based on long-term follow-up data from the ZOE-50 and ZOE-70 trials, Shingrix protection against shingles remains strong for at least 7 to 10 years after the 2-dose series, with little evidence of substantial waning in the follow-up period analyzed so far. This is a marked improvement over the older Zostavax, which showed efficacy declining to approximately 20% after 6 to 8 years. No booster dose is currently recommended for patients who have completed the 2-dose Shingrix series, but CDC and ACIP continue to monitor long-term effectiveness data, and recommendations could be updated as longer follow-up becomes available. Patients who received Zostavax years ago are now recommended to complete a full 2-dose Shingrix series regardless of prior Zostavax history.